Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib’s ability to produce durable remissions in patients, acquired resistance can develop, mo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Reiff, Sean D., Muhowski, Elizabeth M., Guinn, Daphne, Lehman, Amy, Fabian, Catherine A., Cheney, Carolyn, Mantel, Rose, Smith, Lisa, Johnson, Amy J., Young, Wendy B., Johnson, Adam R., Liu, Lichuan, Byrd, John C., Woyach, Jennifer A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2018
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128087/
https://ncbi.nlm.nih.gov/pubmed/30018078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-10-809020
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak